The statement comes after the U.S. Food and Drug Administration flagged problems, including peeling paint and loose debris, during inspections at a U.S. plant in Baltimore that makes the drugmaker's COVID-19 vaccine and asked for remediation of the issues.

(Reporting by Manas Mishra in Bengaluru; Editing by Aditya Soni)